First Bank & Trust Cuts Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

First Bank & Trust decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 49.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,202 shares of the medical research company's stock after selling 1,184 shares during the period. First Bank & Trust's holdings in Thermo Fisher Scientific were worth $598,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bernard Wealth Management Corp. purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $25,000. Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $29,000. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at $30,000. Cassady Schiller Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 89.2% during the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock worth $36,000 after purchasing an additional 33 shares in the last quarter. Finally, VSM Wealth Advisory LLC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $36,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 0.1%

TMO stock traded up $0.49 during midday trading on Thursday, hitting $428.25. The stock had a trading volume of 1,359,321 shares, compared to its average volume of 1,971,505. The company's 50-day moving average price is $409.10 and its 200 day moving average price is $480.59. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The firm has a market cap of $161.66 billion, a PE ratio of 25.12, a price-to-earnings-growth ratio of 2.27 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same period in the prior year, the firm posted $5.11 earnings per share. The business's quarterly revenue was up .2% compared to the same quarter last year. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Analyst Ratings Changes

A number of research firms recently commented on TMO. Royal Bank Of Canada lowered their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Barclays lowered their price target on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a report on Tuesday, June 24th. Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Stifel Nicolaus cut their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Finally, The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $604.05.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.